Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

June 30, 2009

Study Completion Date

January 31, 2011

Conditions
Brain and Central Nervous System TumorsUnspecified Childhood Solid Tumor, Protocol Specific
Interventions
DRUG

irinotecan hydrochloride

DRUG

temozolomide

DRUG

vincristine sulfate

Trial Locations (18)

10032

Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York

13210

SUNY Upstate Medical University Hospital, Syracuse

18107

Lehigh Valley Hospital - Muhlenberg, Bethlehem

35294

Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham

55455

Masonic Cancer Center at University of Minnesota, Minneapolis

55905

Mayo Clinic Cancer Center, Rochester

60614

Children's Memorial Hospital - Chicago, Chicago

75390

Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas

92868

Children's Hospital of Orange County, Orange

98105

Children's Hospital and Regional Medical Center - Seattle, Seattle

94305-5824

Stanford Cancer Center, Stanford

46202-5289

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

02115

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

45229-3039

Cincinnati Children's Hospital Medical Center, Cincinnati

97239-3098

Oregon Health and Science University Cancer Institute, Portland

19104-9786

Children's Hospital of Philadelphia, Philadelphia

M5G 1X8

Hospital for Sick Children, Toronto

H3T 1C5

Hopital Sainte Justine, Montreal

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Children's Oncology Group

NETWORK

NCT00138216 - Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors | Biotech Hunter | Biotech Hunter